Deferred Tax Assets, Valuation Allowance of Eloxx Pharmaceuticals, Inc. from 30 Jun 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Eloxx Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 30 Jun 2011 to 31 Dec 2025.
  • Eloxx Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $94,644,000, a 0.83% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Eloxx Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $94,644,000 +$782,000 +0.83% 31 Dec 2025 10-K 17 Mar 2026 2025 FY
Q4 2024 $93,862,000 -$327,000 -0.35% 31 Dec 2024 10-K 17 Mar 2026 2025 FY
Q4 2023 $94,189,000 +$14,212,000 +18% 31 Dec 2023 10-K 17 Mar 2026 2025 FY
Q4 2022 $79,977,000 +$8,388,000 +12% 31 Dec 2022 10-K 31 Mar 2023 2022 FY
Q4 2021 $71,589,000 +$19,005,000 +36% 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q4 2020 $52,584,000 +$5,902,000 +13% 31 Dec 2020 10-K 30 Mar 2022 2021 FY
Q4 2019 $46,682,000 +$10,813,000 +30% 31 Dec 2019 10-K 12 Mar 2021 2020 FY
Q4 2018 $35,869,000 +$7,726,000 +27% 31 Dec 2018 10-K 06 Mar 2020 2019 FY
Q4 2017 $28,143,000 +$24,120,000 +600% 31 Dec 2017 10-K 14 Mar 2019 2018 FY
Q2 2017 $29,464,000 +$701,000 +2.4% 30 Jun 2017 10-K 13 Oct 2017 2017 FY
Q4 2016 $4,023,000 31 Dec 2016 10-K 16 Mar 2018 2017 FY
Q2 2016 $28,763,000 -$2,589,000 -8.3% 30 Jun 2016 10-K 13 Oct 2017 2017 FY
Q2 2015 $31,352,000 +$4,261,000 +16% 30 Jun 2015 10-K 13 Oct 2016 2016 FY
Q2 2014 $27,091,000 +$5,271,000 +24% 30 Jun 2014 10-K 13 Oct 2016 2016 FY
Q2 2013 $21,820,000 +$1,881,000 +9.4% 30 Jun 2013 10-K 29 Sep 2014 2014 FY
Q2 2012 $19,939,000 +$2,001,949 +11% 30 Jun 2012 10-K 11 Sep 2013 2013 FY
Q2 2011 $17,937,051 30 Jun 2011 10-K/A 26 Oct 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.